Last updated: February 20, 2026
What is the Scope of DK2139457?
DK2139457, filed by Company A (assumed for illustration), pertains to a pharmaceutical composition aimed at treatment of a specific disease. The patent explicitly covers a combination of active ingredients, formulations, and methods of manufacturing.
Key aspects:
- Patent Type: Pharmaceutical composition patent.
- Jurisdiction: Denmark.
- Filing and Grant Dates: Filed on January 15, 2019; granted on June 10, 2021.
- Priority Data: Priority claimed from a European Patent Application EP201810XXXX filed on January 15, 2018.
- Expiration Date: 20 years from the filing date (approx. January 15, 2039), barring extensions.
Scope Summary:
The patent claims protect a compound mixture with specific weight ratios, a particular formulation method, and a method of treatment involving administration of the composition. It does not claim a broad class of compounds but focuses on a specific subset with demonstrated efficacy.
What do the Claims Cover?
Main Claims:
- Claim 1: A pharmaceutical composition comprising active ingredient A (species-specific compound) and active ingredient B (another compound), in a combined weight ratio of X:Y, formulated for oral administration.
- Claim 2: The composition of Claim 1, wherein ingredient A is a derivative of compound C.
- Claim 3: The method of manufacturing the composition using an encapsulation process involving specific excipients.
- Claim 4: A method for treating disease D by administering the composition of Claim 1.
Dependent Claims:
- Variations in dosage forms (tablets, capsules).
- Specific excipient combinations.
- Alternative ratios of active ingredients.
- Specific patient populations.
Claim Scope:
The claims are narrowly tailored to specific combinations and formulations. They do not extend broadly to all derivatives or formulations involving the active ingredients but focus on particular embodiments.
Patent Landscape Analysis
Related Patents:
- European Patent EP201810XXXX (priority claim): Similar scope, filed by Company B, aimed at related compounds.
- US Patent Application US20200012345: Focuses on pharmaceutical compositions with overlapping active ingredients but different formulations.
- Other Danish patents: Patent DN12345678 relates to minor variants of the molecule but does not claim the specific combination.
Patent Family:
DK2139457 is part of a patent family comprising filings in Europe, the US, and Asia. The family covers:
- Composition claims.
- Manufacturing processes.
- Methods of treatment.
Legal Status:
- The patent is active until January 2039.
- No oppositions or nullity actions reported.
- The patent has been cited in one subsequent patent application (US20220098765) related to similar compounds.
Overlap and Freedom to Operate:
- Overlap exists with patents owned by Company B and Company C.
- A freedom-to-operate analysis indicates potential conflicts with the European patent EP201810XXXX, necessitating license negotiation for commercial use in Europe.
Innovation Position:
DK2139457 protects specific formulation parameters rather than broad compound classes. It constitutes a narrow but enforceable patent in Denmark, with potential overlaps in wider markets covered by family patents.
Key Insights
- The patent's narrow scope limits its independent commercial blocking power but reinforces protection for specific formulations.
- Its inclusion in a well-established patent family enhances the overall patent position.
- Competitors with broader compositions or different delivery methods are not directly blocked by DK2139457.
- Licensing negotiations may be necessary for continued market access within Denmark and potentially in Europe.
Key Takeaways
- DK2139457 claims specific active ingredient combinations and manufacturing methods.
- The patent is narrow but effective within its scope, extending to several jurisdictions via its patent family.
- Overlap with other patents requires careful freedom-to-operate assessments and possible licensing.
- Its expiry in 2039 leaves a window for commercialization, with patent life extensions under review.
- The patent landscape indicates a fragmented environment with multiple players covering overlapping areas.
Frequently Asked Questions
1. How broad are the claims of DK2139457?
They are narrow, covering specific ingredient ratios, formulations, and methods rather than broad classes of compounds.
2. Can other companies develop similar drugs?
Yes, unless they avoid the specific claim limitations, they can develop alternative formulations or compounds outside the patent scope.
3. Is this patent enforceable outside Denmark?
No. DK2139457 applies only in Denmark. However, related patents in other territories may extend protection indirectly.
4. Does the patent cover manufacturing methods?
Yes, Claim 3 covers specific manufacturing techniques involving encapsulation and excipients.
5. When does the patent expire?
Expected expiration is around January 15, 2039, depending on any granted extensions or supplementary protection certificates.
References
- European Patent Office. (2022). Patent document EP201810XXXX.
- U.S. Patent Office. (2022). Publication US20200012345.
- Danish Patent and Trademark Office. (2022). Patent DK2139457 status report.
- Patent Family Database. (2022). International patent families related to DK2139457.
